Aurion Biotech, a clinical-stage biotech company aiming to restore vision to millions of patients with regenerative therapies, announced on Wednesday that AURN001, an allogeneic cell therapy for corneal edema, has secured both Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA).
AURN001 is the first therapy of its kind to achieve this dual designation for the treatment of corneal edema secondary to corneal endothelial disease.
BTD expedites development for treatments with promising clinical data, while RMAT recognizes the potential of regenerative therapies for unmet medical needs. These designations aim to accelerate AURN001's path to market, leveraging positive results from ongoing Phase 1/2 trials.
AURN001 has already received regulatory approval in Japan.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals